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Abstract
Background: Higher circulating 25-hydroxyvitamin-D [25(OH)D] concentrations are consistently inversely associated with
colorectal cancer (CRC) risk in observational studies. However, it is unknown whether this association depends on the
functional GC-rs4588*A (Thr436Lys) variant encoding the vitamin D–binding protein-2 (DBP2) isoform, which may affect vita-
min D status and bioavailability.
Methods: We analyzed data from 1710 incident CRC cases and 1649 incidence-density–matched controls nested within three
prospective cohorts of mostly Caucasians. Study-specific incidence rate ratios (RRs) for associations of prediagnostic, season-
standardized 25(OH)D concentrations according to DBP2 isoform with CRC were estimated using multivariable unconditional
logistic regression and were pooled using fixed-effects models. All statistical significance tests were two-sided.
Results: The odds of having 25(OH)D concentrations less than 50 nmol/L (considered insufficient by the Institute of
Medicine) were 43% higher for each DBP2-encoding variant (rs4588*A) inherited (per DBP2 odds ratio [OR] ¼ 1.43, 95%
confidence interval [CI] ¼ 1.27 to 1.62, Ptrend ¼ 1.2  108). The association of 25(OH)D concentrations with CRC risk dif-
fered by DBP2: 25(OH)D concentrations considered sufficient (50 nmol/L), relative to deficient (<30 nmol/L), were as-
sociated with a 53% lower CRC risk among individuals with the DBP2 isoform (RR ¼ 0.47, 95% CI ¼ 0.33 to 0.67), but
with a non–statistically significant 12% lower risk among individuals without it (RR ¼ 0.88, 95% CI ¼ 0.61 to 1.27)
(Pheterogeneity ¼ .01).
Conclusions: Our results suggest that the 25(OH)D-CRC association may differ by DBP isoform, and those with a DBP2-
encoding genotype linked to vitamin D insufficiency may particularly benefit from adequate 25(OH)D for CRC prevention.
Received: May 30, 2019; Revised: September 17, 2019; Accepted: October 11, 2019
© The Author(s) 2020. Published by Oxford University Press.
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Colorectal cancer (CRC) is the second leading cause of cancer-
related death and the third most common cause of cancer
among men and women globally (1). Strong experimental evi-
dence supports that vitamin D may prevent colorectal carcino-
genesis via several mechanisms, including increasing bile acid
catabolism, decreasing inflammation and angiogenesis, and di-
rect effects on cellular proliferation, differentiation, and apopto-
sis (2,3). Although higher circulating 25-hydroxyvitamin D
[25(OH)D] concentrations—used clinically to assess vitamin D
status—are inversely associated with CRC risk in observational
studies (4), randomized clinical trials of the efficacy of vitamin
D supplementation in preventing colorectal neoplasms were
largely null (5–7). Various limitations of these trials, including
sample size, dosing, trial duration, timing of supplementation
in the natural history of the disease, and compliance, that
may have contributed to these null findings have been de-
scribed (5–7). Additionally, the effects of vitamin D supplemen-
tation and circulating 25(OH)D concentrations on vitamin D
metabolism may differ by functional genetic variants, such as
those in the vitamin D–binding protein (DBP) gene, formerly
known as group component (GC) (8,9). However, whether the
25(OH)D-CRC risk association differs by functional GC variants
is unknown. Addressing this is relevant to the National
Institute of Health’s Precision Medicine Initiative aimed at tai-
loring health care recommendations based on individual char-
acteristics such as genotypes (10).
Nearly 90% of circulating 25(OH)D is bound to the DBP, which
maintains stable serum vitamin D stores and regulates free
25(OH)D available to target tissues (11). DBP may also play a role
in fatty acid binding, actin scavenging, and complement-
mediated immune cell chemotaxis (12). Two GC missense var-
iants (rs7041 and rs4588) determine three common DBP protein
“isoforms” (DBP1s, DBP1f, and DBP2, also known as Gc1s, Gc1f,
and Gc2), which are associated with differences in vitamin D
status and vitamin D pathway induction (13,14). Moreover, the
association of 25(OH)D with, and the effects of vitamin D sup-
plementation on, colorectal adenoma risk were reported to be
stronger among those with the DBP2-encoding variant than
among those without it, but whether there is a similar pattern
of effect modification in relation to CRC risk is unknown (8,15).
Accordingly, we hypothesized that higher 25(OH)D concen-
trations would be more strongly inversely associated with CRC
risk among individuals with the DBP2 isoform than among
those without it. We investigated this hypothesis in three pro-
spective case-control studies nested within cohort studies con-
ducted in the United States and Europe.
Methods
Study Population
We conducted an individual-participant, pooled analysis of
data from three prospective cohort studies (1): the European
Prospective Investigation into Cancer and Nutrition (EPIC),
which recruited men and women from the general population
in 10 Western European countries (1992–1998) (16); (2) the
Cancer Prevention Study-II Nutrition Cohort (CPS-II), which
recruited men and women from 21 US states (1992–1993) (17);
and (3) the Nurses’ Health Study (NHS), which recruited female
nurses in the United States (1976) (18). Previously, 1914 incident
CRC cases within these cohorts were identified, and 2249 con-
trols were matched using incidence density sampling with
regards to age, sex (except NHS), and date of blood draw
(4,19,20). Additional details regarding case ascertainment and
matching criteria, available in the Supplementary Methods
(available online), were published previously for EPIC (4,20),
CPS-II (4), and NHS (4,19). Of the combined matched set, 1710
cases and 1649 controls had relevant genotyping information
and were included in this analysis. Each participating cohort
was approved by its respective institutional review board, and
written informed consent was obtained from each participant.
25(OH)D Assays
Total 25(OH)D (D2 and D3) was measured using the US Food and
Drug Administration–approved DiaSorin LIAISON chemilumines-
cence immunoassay (CLIA) in CPS-II (Heartland Assays, Ames,
IA), the OCTEIA enzyme immunoassay (Immuno Diagnostic
Systems, Boldon, UK) in EPIC (20), and a radioimmunoassay at
the laboratory of Dr B.W. Hollis (The Medical University of South
Carolina, Charleston, SC) and the Heartland Laboratory
(Heartland Assays, Ames, IA) in NHS (19). Because 25(OH)D meas-
urements may vary by assay, a subset of control samples from
EPIC and NHS in each 25(OH)D decile were reassayed using the
DiaSorin CLIA at Heartland Assays and were used to calibrate
25(OH)D to this standard assay using the robust linear regression
described previously (21) and in the Supplementary Methods
(available online). The intra-assay coefficient of variance was
4.5% for EPIC, 5.2% for CPS-II, and 13.5% for NHS.
Genotyping
Genotyping was performed using a custom GoldenGate
Universal-plex assay kit (Illumina, CA) in EPIC (22); a custom
Affymetrix genome-wide platform, the Axiom Correct Set
(Affymetrix, CA) in CPS-II (23); and the OmniExpress platform in
NHS (Illumina, CA) (23). Genotyping quality control for CPS-II
and NHS samples was described previously (23). In EPIC, all GC
genotyping was conducted using standard quality control: The
lowest reproducibility frequency across 62 replicate samples
was 0.98; call rates were greater than 95% for all samples and
single-nucleotide polymorphisms.
Individuals with the GC-rs4588*A allele (CA or AA) were clas-
sified as having the DBP2 isoform, whereas those without the A
allele (CC) were classified as having only DBP1 isoforms (13,24).
The two DBP1 (1f and 1s) isoforms, distinguished by GC-rs7041,
were combined in this analysis based on previous studies’
effect-modification findings and our hypothesis (8,15,25,26).
These genotypes perfectly predict the expected amino acid
changes of the circulating protein isoforms as determined in
previous proteomic analyses (24). GC rs3755967 (G>A) was used
as a proxy rs4588 in EPIC; these single-nucleotide polymor-
phisms are in complete linkage disequilibrium (r2 ¼ 1.0) in the
HapMap Spanish and British populations (1000 Genomes Project
Phase 3, LD link, National Cancer Institute, Washington, DC). GC
rs3755967 and rs4588 were in Hardy-Weinberg equilibrium
(P> .05) in each study.
Statistical Analyses
Calibrated 25(OH)D measurements were season standardized
using a cos/sin function described previously (21) and in
the Supplementary Methods (available online). The season-
standardized value may be interpreted as a participant’s pre-
dicted 25(OH)D concentration averaged over the entire year,
accounting for study-specific seasonal variation in 25(OH)D (21).
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We estimated the association of DBP2 inheritance (GC-rs4588
genotype) with 25(OH)D concentrations less than 50 nmol/L, us-
ing unconditional logistic regression; 50 nmol/L is considered the
cut point for vitamin D sufficiency by the Institute of Medicine
(IOM, now the National Academy of Medicine). A two-stage
approach was used to estimate summary odds ratios (ORs):
study-specific odds ratios were calculated in separate uncondi-
tional logistic regression models, and then combined using fixed-
effects models (in sensitivity analyses, the use of mixed-effects
models did not materially affect the results). All study-specific
odds ratios were adjusted for age, sex, and case-control status;
EPIC models were further adjusted for study center. Study-
specific mean 25(OH)D concentrations among DBP1-1, DBP1-2,
and DBP2-2 participants were calculated using general linear re-
gression models adjusted for the same covariates.
We estimated the association of 25(OH)D concentrations,
categorized using IOM-recommended cut points, with CRC risk
using unconditional logistic regression models stratified by
DBP2 isoform inheritance (ie, GC-rs4588 using a dominant
inheritance model). We report associations as incidence rate ra-
tios (RRs), which are estimated by odds ratios in nested case-
control studies in which controls are selected using incidence
density sampling (20). Conditional logistic regression necessi-
tated excluding participants in matched pairs who were discor-
dant on DPB2-encoding genotypes; however, in sensitivity
analyses, the results from conditional and unconditional logis-
tic regression did not materially differ, so unconditional logistic
regression was chosen to maximize our sample size and statis-
tical power. A dominant inheritance model was chosen based
on previous findings of effect modification by DBP2 for the asso-
ciation of 25(OH)D with colorectal adenoma risk (15) and to
maximize statistical efficiency given the rarity of the DBP2-2
genotype, especially in the smaller CPS-II and NHS studies. A
two-stage approach was used to estimate summary relative
risks: study-specific relative risks were calculated in separate lo-
gistic regression models, and then combined using fixed-effects
models (in sensitivity analyses, the use of mixed-effects models
did not materially affect the results). Study-specific relative
risks were adjusted for study-specific matching factors
(Supplementary Methods, available online), body mass index
(BMI) (continuous, kg/m2), and physical activity (combined rec-
reational and household activity metabolic equivalent hours
per week, quartiles). Potential covariates, chosen based on bio-
logical plausibility and previous literature, included education,
smoking, and total dietary intakes of energy, calcium (from food
and supplements), fruits and vegetables, red and processed
meats, and alcohol; of these, only those that affected the rela-
tive risks by 10% or greater were included in the final models
(see the Tables’ footnotes). Between-study heterogeneity was
evaluated using the I2 statistic. Effect modification of the RRs by
DBP2 was evaluated using meta-regression (27).
Because the cut points for vitamin D status are debated, in
separate analyses we included an additional upper category
( 75 nmol/L) and collapsed the lower IOM categories
(< 50 nmol/L) because other professional societies use these val-
ues to define vitamin D sufficiency and deficiency, respectively
(28). In all models, the lowest 25(OH)D category was used as the
reference. To assess the significance of trend in CRC risk across
the three- and four-level 25(OH)D categories, participants were
assigned the study-specific median value of their respective
25(OH)D category, and the study-specific coefficients were
pooled using fixed-effects models (27).
All statistical tests were two-sided; a P less than .05 or a 95%
confidence interval (CI) that excluded 1.0 was considered
statistically significant. Analyses were performed using SAS
version 9.3 (Cary, NC), except for the meta-analyses performed
in STATA version 12.1 (College Station, TX).
Results
Selected characteristics of the study participants, by cohort and
case-control status, are summarized in Table 1; tumor charac-
teristics (site and stage) of CRC cases are presented in
Supplementary Table 1 (available online). In EPIC, CPS-II, and
NHS, the median ages at blood draw were 59, 75, and 59 years;
the median times from blood draw to CRC diagnosis were 3.6,
3.2, and 9.6 years; and the frequencies of the DBP2-encoding al-
lele were 0.29, 0.26, and 0.28, respectively.
Individuals with the DBP2 isoform were more likely than
those with DBP1 isoforms to have 25(OH)D concentrations less
than 50 nmol/L (per DBP2 OR ¼ 1.43, 95% CI: 1.27 to 1.62, Ptrend ¼
1.2  108) (Table 2). Mean 25(OH)D concentrations were lower
in EPIC (DBP1-1: 43.1, DBP2-2: 40.8, DBP2-2: 37.5 nmol/L) than in
NHS (DBP1-1: 69.2, DBP1-2: 55.5, DBP2-2: 63.6 nmol/L) or CPS-II
(DBP1-1: 62.3, DBP1-2: 61.5, DBP2-2: 64.3 nmol/L) (Supplementary
Table 2, available online).
Higher 25(OH)D concentrations were more strongly associated
with lower CRC risk among individuals with the DBP2 isoform
than among those with only DBP1 isoforms (Table 3). Among
those with DBP2, 25(OH)D concentrations of 30 to 49, 50 to 74, and
75 or greater nmol/L, relative to less than 30 nmol/L, were associ-
ated with statistically significant 31%, 56%, and 60% lower risk of
CRC, respectively (Ptrend ¼ 5.8  10–5). Among those with only
DBP1 isoforms, the corresponding RRs for CRC risk were 20%
higher, 8% lower, and 34% lower (for concentrations of 30 to 49,
50 to 74, and 75 or greater nmol/L, relative to less than 30 nmol/L
[Ptrend ¼ .01; Pheterogeneity for DBP2 ¼ .02, .02, and .21], respectively).
Concentrations of 50 or greater nmol/L relative to less than
30 nmol/L were associated with a statistically significant 53%
lower CRC risk among those with DBP2 (Ptrend ¼ .0001), and non–
statistically significant 12% lower risk among individuals with
only DBP1 isoforms (Ptrend¼ .09; Pheterogeneity by DBP2 ¼ .01).
The pattern of effect modification by DBP2 was most pro-
nounced in the larger EPIC study (Supplementary Table 3, avail-
able online), but there was no evidence of statistically
significant study heterogeneity in the meta-analyses (I2 ¼ 0.0–
20.1%, Pheterogeneity by study > .28 for all meta-estimates
[Supplementary Table 4, available online]). Our findings did not
substantially differ by BMI or follow-up time between blood draw
and CRC diagnosis (stratified at study-specific means), tumor site
(colon or rectum), or sex (in EPIC and CPS-II; results not shown).
Discussion
Our findings suggest that associations of 25(OH)D concentra-
tions with CRC risk differ by common, inherited vitamin D–
binding protein isoforms, and that individuals with DBP2—who
may be predisposed to vitamin D insufficiency relative to indi-
viduals with DBP1 isoforms—may particularly benefit from
maintaining sufficient vitamin D concentrations for CRC pre-
vention. To our knowledge, this is the first study to report that
the 25(OH)D-CRC association differs by DBP isoform.
DBP2 is encoded by the functional GC-rs4588 polymorphism
(C>A) resulting in a Thr (DBP1) ! Lys (DBP2) amino acid substitu-
tion at residue 436 (29,30). Although the physiologic consequences
of the isoforms have not been fully elucidated, consistent with pre-
vious studies (31–33), the DBP2-encoding variant was strongly
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associated with lower circulating 25(OH)D concentrations and
higher odds of vitamin D insufficiency in our study population.
This association may be due to differences in circulating DBP con-
centrations (20–30% lower among DBP2 homozygotes relative to
DBP1 homozygotes were reported in studies that did not use the
isoform-biased monoclonal R&D assay (24,34–37)) because DBP
mediates the renal reabsorption of 25(OH)D and prolongs its circu-
lating half-life (25,29,38). Some studies suggest that the DBP2 iso-
form also has the lowest binding affinity to 25(OH)D, which, in
addition to lower DBP concentrations, could lead to higher levels of
free 25(OH)D (11,24,39,40). This may underlie the higher induction
of vitamin D target genes by 25(OH)D in cultured monocytes and
colon cancer cell lines with DBP2 relative to cells cultured with
DBP1 isoforms (41,42). Normal and neoplastic colon tissues express
the vitamin D-receptor (VDR) and are able to locally convert
25(OH)D to the VDR-activating 1, 25(OH)2D form, which may play
an important role in colorectal carcinogenesis via modulating cell
growth, inflammation, angiogenesis, and apoptosis (43,44). Taken
together, we hypothesize that individuals with the DBP2 isoform
may particularly benefit from higher 25(OH)D concentrations be-
cause these concentrations may lead to higher vitamin D–
pathway activation and may be needed to compensate for DBP2
individuals’ reduced capacity to otherwise maintain adequate
25(OH)D concentrations.
Supporting this hypothesis are findings from other observa-
tional studies and randomized, controlled trials (RCT) that
reported similar patterns of effect modification by DBP2. In a US
case-control study of individuals of European ancestry, 25(OH)D
concentrations of 50 or greater relative to less than 50 nmol/L
were associated with lower risk of incident, sporadic colorectal
adenoma among those with DBP2 (OR ¼ 0.51, 95% CI ¼ 0.33 to
0.81), but not among those without DBP2 (OR ¼ 1.11, 95% CI ¼
0.68 to 1.92) (Pinteraction ¼ .05) (15). Findings from two other obser-
vational studies (including an NHS study that used the same
matched case-control set used in our analysis) suggest that the
25(OH)D-CRC risk association is stronger among those with DBP
concentrations less than the median, which provides indirect
support of our findings, given the strong association of DBP2
with lower DBP concentrations (19,45). Additionally, although
the reported effects of vitamin D supplementation on colorectal
neoplasm prevention in RCTs have largely been null (7,46), it is
possible that the effects of vitamin D supplementation on
25(OH)D concentrations and colorectal neoplasm prevention
may also depend on the functional DBP2 isoform (8,9). In two
trials, vitamin D supplementation increased 25(OH)D concentra-
tions more among those with the DBP2-encoding relative to
DBP1-encoding genotypes (9,47). Moreover, in a large RCT
(n¼ 2259) (8), the “interaction relative risk”—ratio of the vitamin
D supplementation RR per DBP2-encoding minor allele divided
by that for the DBP1-encoding major allele—was 0.82 (95% CI ¼
0.69 to 0.98), indicating that the effect of vitamin D supplemen-
tation on reducing adenoma recurrence was statistically signifi-
cantly stronger with each DBP2-encoding variant inherited
(Pinteraction ¼ .03).
Our findings may help explain certain inconsistencies in the
literature regarding vitamin D concentrations, GC genotypes,
and CRC risk. In a recent international pooling project of 17
cohorts, the study-specific RRs for CRC with each 25-nmol/L in-
crease in 25(OH)D were mostly inverse, but they varied from
1.17 to 0.63, with only five being statistically significant (4). In
addition to differences in sample size that may affect the preci-
sion of the estimates, this heterogeneity may, in part, be due to
differences in DBP2 frequency in different study populations be-
cause DBP2 frequency varies by geographic area and ethnicityT
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(from 0.01 to 0.41 internationally, and from 0.21 to 0.41 in
European and white American populations) (48). Additionally,
although the DBP2-encoding GC-rs4588 variant is associated
with lower 25(OH)D concentrations, it was not associated with
CRC risk in genome-wide association or Mendelian randomiza-
tion studies (49–51). The potential interaction between 25(OH)D
concentrations and DBP2 in relation to CRC risk could contrib-
ute to these null findings.
Strengths of our study include the use of data from three
prospective cohorts in the United States and Europe, with par-
ticipants from geographically diverse areas. We also used
season-adjusted 25(OH)D concentrations, thereby reducing mis-
classification of vitamin D status, which may vary throughout
the year and in study populations living at different latitudes.
Given that 25(OH)D measurements may vary by assay type, har-
monization of 25(OH)D levels to a standard assay is another
Table 2. Study-specific and summary associations of vitamin D–binding protein isoforms with vitamin D nonsufficiency* in the EPIC, CPS-II,
and NHS cohorts
Study DBP isoform (rs4588 genotype) <50 nmol/L (nonsufficient) 50 nmol/L (sufficient) <50 vs. 50 nmol/LOR (95% CI)† Ptrend
EPIC
DBP1-1 (CC) 674 254 1.00 (Referent)
DBP1-2 (CA) 560 173 1.41 (1.11 to 1.78)
DBP2-2 (AA) 138 26 2.59 (1.63 to 4.42)
Per DBP2 isoform (per A allele) 1372 453 1.52 (1.26 to 1.82) 8.7  106
CPS-II
DBP1-1 (CC) 78 180 1.00 (Referent)
DBP1-2 (CA) 53 120 1.03 (0.67 to 1.57)
DBP2-2 (AA) 12 20 1.47 (0.68 to 3.18)
Per DBP2 isoform (per A allele) 143 320 1.13 (0.82 to 1.55) .42
NHS
DBP1-1 (CC) 149 421 1.00 (Referent)
DBP1-2 (CA) 120 282 1.20 (0.91 to 1.60)
DBP2-2 (AA) 47 52 2.55 (1.65 to 3.95)
Per DBP2 isoform (per A allele) 316 755 1.46 (1.20 to 1.77) .0002
All studies‡
DBP1-1 (CC) 901 855 1.00 (Referent)
DBP1-2 (CA) 733 575 1.27 (1.08 to 1.50)
DBP2-2 (AA) 197 98 2.36 (1.74 to 3.19)
Per DBP2 isoform (per A allele) 912 2447 1.43 (1.27 to 1.62) 1.2  108
25(OH)D ¼ 25-hydroxyvitamin D; CI ¼ confidence interval; CPS-II ¼ Cancer Prevention Study-II; DBP ¼ vitamin D–binding protein; EPIC ¼ European Prospective
Investigation into Cancer and Nutrition; NHS ¼ Nurses’ Health Study; OR ¼ odds ratio.
*According to 2011 Institute of Medicine recommendations based on circulating 25(OH)D concentrations; 25(OH)D blood concentrations were calibrated to the same as-
say and seasonally adjusted using the method described by Gail et al. (21).
†Odds ratio and 95% confidence interval estimated in logistic regression models adjusted for age (continuous), sex, study center (for EPIC models), and case-control status.
‡Odds ratios and 95% confidence intervals estimated in fixed-effects meta-analyses (I2 ¼ 0.0 to 22.1; Pheterogeneity by study > .25 for all summary estimates).
Table 3. Summary incidence rate ratios (RR) of colorectal cancer according to vitamin D status and functional vitamin D–binding protein (DBP)
isoforms in the EPIC, CPS-II, and NHS cohorts
DBP1-1 (rs4588 CC)† DBP1-2 or DBP2-2 (rs4588 CA or AA)‡
25(OH)D concentration
(IOM-defined vitamin
D status)*
No.
cases
No.
controls RR (95% CI)§ Ptrend
No.
cases
No.
controls RR (95% CI)§ Ptrend
Pheterogeneity
by DBP2
< 30 nmol/L (deficient)* 144 104 1.00 (Referent) 218 107 1.00 (Referent)
30 to < 50 nmol/L (insufficient) 386 267 1.20 (0.86 to 1.67) 320 285 0.69 (0.51 to 0.95) .02
50 to < 75 nmol/L (sufficient) 266 288 0.92 (0.63 to 1.34) 191 266 0.44 (0.27 to 0.73) .02
 75 nmol/L (beyond sufficient) 105 196 0.66 (0.37 to 1.16) 0.01 80 136 0.40 (0.23 to 0.68) 5.8  105 .21
< 30 nmol/L (deficient) 144 104 1.00 (Referent) 218 107 1.00 (Referent)
30 to < 50 nmol/L (insufficient) 386 267 1.19 (0.85 to 1.66) 320 285 0.69 (0.50 to 0.94) .02
 50 nmol/L (sufficient) 371 484 0.88 (0.61 to 1.27) 0.09 271 402 0.47 (0.33 to 0.67) .0001 .01
< 50 nmol/L (nonsufficient) 530 371 1.00 (Referent) 538 392 1.00 (Referent)
 50 nmol/L (sufficient) 371 484 0.79 (0.63 to 1.00) 271 402 0.60 (0.47 to 0.76) .10
25(OH)D ¼ 25-hydroxyvitamin D; CI ¼ confidence interval; CPS-II ¼ Cancer Prevention Study-II; DBP ¼ vitamin D–binding protein; EPIC ¼ European Prospective
Investigation into Cancer and Nutrition; IOM ¼ Institute of Medicine; NHS ¼ Nurses’ Health Study; RR ¼ incidence rate ratio.
*The 25(OH)D blood concentrations were calibrated to the same assay and seasonally adjusted using the method described by Gail et al. (21).
†Participants with no minor allele at GC-rs4588 (rs4588*CC genotype) were defined as not having the DBP2 isoform (or only DBP1 isoforms).
‡Participants with a minor allele at GC-rs4588 (rs4588*CA or rs4588*AA genotypes) were defined as having the DBP2 isoform.
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strength of this study, providing more reliable meta-estimates
and the ability to assess 25(OH)D using absolute clinical cut
points—a limitation in most prior meta-analyses.
Our study also has several limitations. IOM cut points for vi-
tamin D status are based on skeletal health research because
their guidelines currently cite insufficient evidence to inform
recommendations for nonskeletal health outcomes (28,52).
Larger studies are needed to investigate more precise categories
of 25(OH)D that may be relevant to CRC risk. Data for certain po-
tential confounding factors (eg, aspirin or multivitamin use)
were not available in EPIC; however, adjusting for these covari-
ates in the CPS-II and NHS models did not materially affect the
results. Additionally, prediagnostic 25(OH)D was measured only
once, although it may still have been a relatively good indicator
of long-term vitamin D status given that previous studies esti-
mated within-person correlations between 0.53 and 0.81 for re-
peated 25(OH)D measures taken 1 to 11 years apart (53,54).
Although our meta-estimates were largely driven by the
estimates from EPIC because of its much larger sample size—
especially for those with lower 25(OH)D concentrations—be-
tween-study heterogeneity was minimal. Last, because the
frequency and effects of DBP isoforms may differ by race or eth-
nicity (29,48), our findings may not be generalizable to other
populations.
In conclusion, our findings suggest that the association of cir-
culating vitamin D concentration with CRC risk may differ by
common, inherited genotypes encoding vitamin D–binding pro-
tein isoforms. Individuals with the DBP2 isoform—linked to vita-
min D insufficiency—may particularly benefit from maintaining
adequate vitamin D concentrations for CRC prevention.
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